Printer Friendly

PHOENIX LASER SYSTEMS INC. SHIPS SURGICAL LASER WORKSTATION FOR GLAUCOMA TRIALS

 PHOENIX LASER SYSTEMS INC. SHIPS SURGICAL LASER
 WORKSTATION FOR GLAUCOMA TRIALS
 SAN FRANCISCO, Feb. 5 /PRNewswire/ -- Phoenix Laser Systems Inc. (NASDAQ: PXLSD) today announced that it has shipped a surgical laser workstation to California Pacific Medical Center in San Francisco, where clinical trials for use in the treatment of glaucoma will be initiated under the direction of Dr. Robert Stamper. The Phoenix surgical laser workstation employs technology that can perform micro- surgery non-invasively within the eye without damaging surrounding tissue.
 Dr. Stamper is chairman of the Department of Ophthalmology at California Pacific Medical Center, a fellow of the American Academy of Ophthalmology and a member of the FDA's Ophthalmic Devices Advisory Panel. Dr. Stamper has agreed to act as Medical Monitor for Phoenix's glaucoma clinical trials.
 Joann Schulz, Phoenix president and chief operating officer, stated, "We view this development as an extremely significant breakthrough in the field of eye care. Phoenix offers an extremely promising new form of treatment for glaucoma, a chronic disease, which is one of the leading causes of blindness in the United States. Historically, glaucoma treatment has been less than successful because of the problem of patient compliance with long-term drug therapy and the difficulty of successfully performing current surgical procedures for glaucoma. Dr. Stamper will lead Phoenix' studies into new non- invasive laser procedure for glaucoma which has the potential to change the way in which glaucoma is managed. We are pleased to be initiating these studies at California Pacific Medical Center with Dr. Stamper, who is a leader in the field of glaucoma treatment."
 Phoenix Laser Systems Inc. is a developer of integrated laser workstations primarily for use in medicine. The company's initial efforts have been focused on the development of its first product, the Ophthalmic Workstation. The company's technology permits surgery designed to correct nearsightedness, farsightedness, and astigmatism, as well as a large number of eye disorders which are untreatable or only partially treatable with current technology.
 -0- 2/5/92
 /CONTACT: Michelle Coon of Phoenix Laser Systems Inc., 415-922-4061/
 (PXLSD) CO: Phoenix Laser Systems Inc. ST: California IN: MTC SU:


RM -- SF010 -- 7442 02/05/92 18:53 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 5, 1992
Words:357
Previous Article:MICHAELS SALES RISE 9 PERCENT IN JANUARY PUTTING FY91 AT RECORD $411 MILLION
Next Article:CHEVRON ANNOUNCES CHANGE IN CRUDE PRICES
Topics:


Related Articles
PHOENIX LASER SYSTEMS INC. ANNOUNCES DR. J. JAMES ROWSEY, M.D., AS CORNEAL CONSULTANT
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
SUMMIT TECHNOLOGY ANNOUNCES FDA APPROVAL TO BEGIN SECOND PHASE OF U.S. CLINICAL TRIALS USING HOLMIUM LASER FOR TREATMENT OF FARSIGHTEDNESS
PHOENIX LASER SYSTEMS INC. RETAINS NOMURA SECURITIES INTERNATIONAL INC. AND JOSEPHTHAL LYON & ROSS INC. AS FINANCIAL ADVISORS
PHOENIX LASER SYSTEMS ANNOUNCES TERMINATION OF NEGOTIATIONS WITH STORZ INSTRUMENT COMPANY
ISL FILES IDEs FOR NEARSIGHTEDNESS AND A NOVEL GLAUCOMA TREATMENT
ISL REPORTS THIRD QUARTER RESULTS
PHOENIX LASER SYSTEMS SHIPS SURGICAL WORKSTATION TO ADDITIONAL SITE FOR ANIMAL AND CLINICAL TRIALS
DELAWARE CHANCERY COURT RULING PROTECTS PHOENIX
PHOENIX LASER SYSTEMS ANNOUNCES CHANGE OF MANAGEMENT

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters